SCHEMBL26046781

SCHEMBL26046781

COC(=O)c1cc(F)c(N)c(C(C)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.46
▸ POLB P06746 3/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ GAA P10253 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ XDH P47989 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ FUT7 Q11130 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ MAPT P10636 3/20 0.44
▸ HPGD P15428 2/20 0.44
▸ GLA P06280 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ ATM Q13315 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3445770 0.86 HDAC1 (0.57) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL23970940 0.81 KDM4E (0.51) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL3431753 0.80 KDM4E (0.44) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL31701857 0.79 KDM4E (0.48) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL22642968 0.79 KDM4E (0.48) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL24901830 0.78 GAA (0.47) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL3652117 0.78 KDM4E (0.47) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL3653125 0.78 HDAC1 (0.49) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL18398444 0.77 KDM4E (0.46) KDM4EPOLBL3MBTL1GAALMNA
SCHEMBL8641593 0.76 ALDH1A1 (0.54) KDM4EPOLBL3MBTL1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023164358-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 — — WO disclosed
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS ASCLETIS BIOSCIENCE CO., LTD. (CN) 2023-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271949-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 KDM4E 2684/4885POLB 4841/4885L3MBTL1 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback